SG3 Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

SG3 Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-40,000	Closed	-$398K	–	614
2022 Q1	$398K	Hold	40,000	–	–	0.01%	655
2021 Q4	$471K	Buy	+40,000	New	+$492K	0.01%	636
2021 Q3	–	Sell	-15,000	Closed	-$209K	–	1128
2021 Q2	$209K	Sell	15,000 -57,000	-79%	-$866K	0.01%	821
2021 Q1	$1.33M	Buy	72,000 +42,000	+140%	+$859K	0.03%	520
2020 Q4	$530K	Buy	30,000 +15,000	+100%	+$263K	0.01%	718
2020 Q3	$230K	Buy	+15,000	New	+$282K	0.01%	709

Other funds holding KNSA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

SG3 Management's KNSA Position: Q3 2021 in Review

SG3 Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2021, closing a stake of 8,500 shares — an estimated $118K sold.

SG3 Management first reported a position in KNSA in Q1 2021 and held it in 2 quarters. The position peaked at $361K in Q1 2021. 101 funds tracked by Wall St. Rank hold KNSA as of Q3 2021.

SG3 Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 8,500 Kiniksa Pharmaceuticals shares in Q3 2021, an estimated $118K.
SG3 Management first reported a position in Kiniksa Pharmaceuticals in Q1 2021 and held it in 2 quarters.
SG3 Management's Kiniksa Pharmaceuticals position peaked at $361K in Q1 2021.
101 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.